Landos Biopharma Inc - ESG Rating & Company Profile powered by AI
This analysis of Landos Biopharma Inc was prepared by All Street Sevva using leading Cognitive Robots. This ESG score for Landos Biopharma Inc indicates its transparency towards the UN SDGs. Complete ESG assessment of Landos Biopharma Inc can be accessed by signing in.
Landos Biopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 3.2, social score of 4.8 and governance score of 4.0.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1412 | Vallon Pharmaceuticals Inc | 4.1 | High |
| 1412 | Vectura Group PLC | 4.1 | High |
| 1443 | Landos Biopharma Inc | 4.0 | High |
| 1443 | Adaptive Biotechnologies Corp | 4.0 | High |
| 1443 | Ascletis Pharma Inc | 4.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Landos Biopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Landos Biopharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Landos Biopharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Landos Biopharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Landos Biopharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Landos Biopharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Landos Biopharma Inc offer flexible work?
Sign up for free to unlockDoes Landos Biopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Landos Biopharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Landos Biopharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Landos Biopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Landos Biopharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Landos Biopharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Landos Biopharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Landos Biopharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Landos Biopharma Inc disclose water use targets?
Sign up for free to unlockDoes Landos Biopharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Landos Biopharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Landos Biopharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Landos Biopharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Landos Biopharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Landos Biopharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Landos Biopharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Landos Biopharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Landos Biopharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Landos Biopharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Landos Biopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Landos Biopharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Landos Biopharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Landos Biopharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Landos Biopharma Inc disclose its waste policy?
Sign up for free to unlockDoes Landos Biopharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Landos Biopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Landos Biopharma Inc disclose energy use targets?
Sign up for free to unlockDoes Landos Biopharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Landos Biopharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Landos Biopharma Inc
These potential risks are based on the size, segment and geographies of the company.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.